PD Dr. rer. nat. Constanca Figueiredo

Institute for Transfusion Medicine



The high variability of the human leukocyte antigen (HLA) remains a major hurdle in transplantation and to the application of in vitro pharmed cell products. Our research group aims at the development of innovative strategies to decrease the immunogenicity of cells, tissues and organs to facilitate their use in allogeneic transplantation. The application of HLA-universal cell-based therapies has the potential to reduce the need for immunosuppression and represent an alternative option for strong alloimmunised patients with lower probabilities to find a compatible tissue or organ. Beside the modification of native tissues and organs, our group focuses in the large-scale production of low immunogenic cell types such as platelets and endothelial cells from HLA-universal induced pluripotent stem cells. The generation of HLA-universal cell products represents a new step in the field of regenerative medicine.

Figueiredo Group